Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 238 participants.
Also called NCT07715279
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 238 participants
- Sponsor
- Registry
-
NCT07715279 -
ChiCTR2500108507
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07715279. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-24 (actual); primary completion 2029-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression
- Acronym
- VERIFICATION
- Condition
- Calcific Aortic Valve Disease
- Condition
- AORTIC VALVE DISEASES
- Condition
- Aortic Valve Stenosis
- Intervention (Drug)
- Vericiguat (BAY1021189)
- Intervention (Drug)
- Placebo
- Lead sponsor
- West China Hospital
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct07715279- Content hash
58ff36526e8430abf02c5f09cfc8d9d492edda097cca0f2398e12017495feffa